Search Count: 1
 |
Identification Of The Clinical Development Candidate Mrtx849, A Covalent Krasg12C Inhibitor For The Treatment Of Cancer
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.94 Å Release Date: 2020-04-22 Classification: HYDROLASE/INHIBITOR Ligands: GDP, MG, M1X |